Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals, Inc.

Tarsus (NASDAQ:TARS) is a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care.

Armentum Partners

Horowitz Group

Vivo Capital

Aperture Venture Partners

Visionary Venture Fund

Flying L Partners

Frazier Healthcare Partners

The first and only FDA-approved treatment for Demodex blepharitis (DB) is now available! We’re delighted to introduce this new therapeutic to the eye care community and thrilled at its potential to help many patients living with this disease.

We are so appreciative of our superstar Tarsus team and the many partners who worked diligently to make this important milestone happen. 

Read the full press release here: https://lnkd.in/eEQW3SEv

🌺 Aloha from the Hawaiian Eye & Retina 2024 Meeting! 

We love kicking off the New Year by attending this important and engaging meeting! This year, we had the privilege of connecting with leading experts in eye care across a variety of different platforms to share experiences about Demodex blepharitis and eyelid health. We appreciate the unique perspectives and compelling discussion and look forward to continuing the dialogue as we move further into 2024. 

Today, we commemorate the incredible life and impact of Dr. Martin Luther King Jr.

His unwavering dedication to justice, equality, and unity continues to inspire us. Dr. King had a vision for a brighter, more inclusive future, and we strive to honor that vision in everything we do at Tarsus.

This #MLKDay, we encourage our Tarsans to volunteer in their communities and reflect on Dr. King's commitments to peace, service, and education.

The Tarsus crew celebrated the holidays and rang in the New Year traveling, relaxing and spending time with loved ones!

We prioritize the health and well-being of our Tarsans and look forward to this important recharge break at the end of each year. Swipe through to see some highlights of our winter wellness week.

Discover more about the values that shape our culture: https://lnkd.in/eGeFU8_E

As we bid farewell to 2023, we’d like to reflect on what an incredible year it’s been.

2023 was a milestone year – we received FDA approval for the first and only treatment for Demodex blepharitis and just a few weeks into launch, we are well on our way to helping millions of potential patients. We experienced tremendous growth as an organization, more than doubling in size, and we were recognized by numerous independent companies as a great place to work.

We are grateful to our investigators, eye care provider partners, patients and our passionate team of Tarsans who helped us get to where we are today.

We are inspired and motivated to start 2024 and continue to deliver on our vision to make a meaningful difference in eye care and to the patients we serve. We wish everyone a happy and healthy holiday season.

See here for XDEMVY prescribing info: https://bit.ly/3Rrf4YB

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	175K -	456K 160.57%	2.24M 390.57%	8.68M 288.02%	9.91M 14.17%	18.15M 83.14%
accumulated other comprehensive income loss	-1K -		-171.97M -		-74K -	-2K 97.30%
cash and cash equivalents	2.35M -	57.95M 2,360.81%	168.13M 190.12%	171.33M 1.91%	71.66M 58.17%	224.95M 213.91%
cash and short term investments	2.35M -	57.95M 2,360.81%	168.13M 190.12%	171.81M 2.19%	217.03M 26.31%	227.44M 4.80%
common stock	1K -	2K 100%	4K 100%	4K 0%	5K 25%	5K 0%
deferred revenue
deferred revenue non current						1.51M -
deferrred tax liabilities non current						733K -
goodwill
goodwill and intangible assets						3.87M -
intangible assets						3.87M -
inventory					4.76M -	3.11M 34.76%
long term debt		100K -	549K 449%	585K 6.56%	19.43M 3,222.05%	29.82M 53.44%
long term investments					371K -	631K 70.08%
net debt	-2.35M -	-57.79M 2,353.84%	-167.30M 189.50%	-169.44M 1.28%	-51.51M 69.60%	-193.22M 275.14%
net receivables	4K -	36K 800%	20K 44.44%	92K 360%	3.58M 3,793.48%	17.71M 394.53%
other assets						1 -
other current assets	24K -		2.51M -	4.04M 61.41%	4.77K 99.88%	7.87M 164,951.37%
other current liabilities	4K -	299K 7,375%	2.87M 859.20%	1.49M 47.98%	4.80M 221.58%	18.39M 283.26%
other liabilities
other non current assets		6K -	81K 1,250%	1.13M 1,290.12%	585K 48.05%	1.51M 158.80%
other non current liabilities	3.56M -	63.40M 1,678.96%	56K 99.91%	114K 103.57%	100K 12.28%	233K 133%
othertotal stockholders equity	10K -	27K 170%	198.82M 736,274.07%	213.40M 7.33%	301.73M 41.39%	441.64M 46.37%
preferred stock			171.97M -
property plant equipment net	6K -	280K 4,566.67%	1.24M 341.43%	1.83M 47.98%	1.53M 16.24%	3.35M 118.54%
retained earnings	-1.36M -	-6.03M 342.38%	-32.84M 444.33%	-46.67M 42.10%	-108.76M 133.04%	-244.66M 124.94%
short term debt		64K -	282K 340.63%	1.31M 363.12%	721K 44.79%	398K 44.80%
short term investments				483K -	145.37M 29,996.48%	2.50M 98.28%
tax assets						733K -
tax payables				55K -	14K 74.55%
total assets	2.39M -	58.32M 2,341.02%	171.97M 194.90%	178.91M 4.03%	227.86M 27.36%	266.22M 16.84%
total current assets	2.38M -	58.03M 2,335.17%	170.66M 194.08%	175.95M 3.10%	225.38M 28.09%	256.13M 13.65%
total current liabilities	179K -	819K 357.54%	5.39M 557.75%	11.48M 113.07%	15.43M 34.42%	36.94M 139.39%
total debt		164K -	831K 406.71%	1.89M 127.56%	20.16M 965.84%	31.73M 57.44%
total investments				483K -	145.74K 69.83%	3.13M 2,044.96%
total liabilities	3.74M -	64.32M 1,618.43%	5.99M 90.68%	12.18M 103.22%	34.96M 187.12%	69.24M 98.03%
total liabilities and stockholders equity	2.39M -	58.32M 2,341.02%	171.97M 194.90%	178.91M 4.03%	227.86M 27.36%	266.22M 16.84%
total non current assets	6K -	286K 4,666.67%	1.32M 360.49%	2.96M 124.37%	2.49M 15.80%	10.09M 305.67%
total non current liabilities	3.56M -	63.50M 1,681.76%	605K 99.05%	699K 15.54%	19.53M 2,694.56%	32.30M 65.35%
total stockholders equity	-1.35M -	-6.00M 343.50%	165.98M 2,864.03%	166.73M 0.45%	192.90M 15.70%	196.99M 2.12%

COM:TARSUSRX

Tarsus Pharmaceuticals, Inc.

Last Close

46.40

22/11 21:00

Market Cap

1.07B

Beta: -

Volume Today

589.21K

Avg: -

Preview